Pfizer Advances Avelumab In Ovarian Cancer With Syndax Combo Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase I/II trial will combine Syndax's entinostat, an HDAC inhibitor, with Pfizer/Merck KGaA's PD-L1 inhibitor avelumab. The antibody is the first immunotherapy to reach Phase III in platinum-resistant/refractory ovarian cancer.